Abstract
Cardiovascular disease is a major cause of morbidity and mortality among patients with chronic kidney disease. Dyslipidemia is a common complication in CKD patients and is associated with the decline in GFR. A cross-sectional, observational study was conducted in 60 CKD patients in different stages and 50 healthy population. Total cholesterol, HDL, LDL and Triglyceride were analysed in all the subjects. Triglyceride, total cholesterol and LDL were significantly increased while, HDL was significantly decreased in the CKD patients. Early diagnosis and management of dyslipidemia in CKD patients is important for positive outcome.
Keywords: Chronic kidney disease, HDL, LDL, total cholesterol, triglyceride.
References
- Parmar JA, Joshi AG, Chakrabarti M. Dyslipidemia and chronic kidney disease. ISRJ. 2014;3:396–397.
- Charles RH, Terry AJ. Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol. 2008;51:2375–2384.
- King W MA, Edward L Greene, Leopold Raij. Cardiovascular risk factors in chronic renal failure and hemodialysis populations. Am J kidney Dis.1992; 6:505-513.
- Ahmed MH, Khalil AA. Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant. Saudi J Kidney Dis Transplant. 2010;21:1021–1029.
- Balode AA, Khan ZH. Serum lipid profile in chronic kidney disease patients on haemodialysis. IJAR. 2013;3:20–22.
- Lacquaniti A, Bolignano D, Donato V, Bono C, Fazio MR, Buemi M. Alterations of lipid metabolism in chronic nephropathies: mechanisms, diagnosis and treatment. Kidney Blood Press Res 2010;33:100–10.
- Cases A, Coll E. Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int Suppl. 2005;(99):S87–S93.
- Weiner DE, Sarnak MJ. Managing dyslipidemia in chronic kidney disease. J Gen Intern Med. 2004;19:1045–1052.
- Shurraw S, Tonelli M. Statins for treatment of dyslipidemia in chronic kidney disease. Perit Dial Int. 2006;26:523–539.
- Wanner C, Ritz E. Reducing lipids for CV protection in CKD patients current evidence. Kidney Int. 2008;74:24–28.
- O Attman, Alaupovic P, M. Tavella , C Knignt , Gibson C. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure. Nephrol dial transplant. 1996; 11:63-69.
- Kwan BCH, Kronenberg F, Beddhu S, Cheung AK. Lipoprotein Metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol. 2007;18:1246–1261.
- Tsimihodimos V, Mitrogianni Z, Elisaf M. Dyslipidemia associated with chronic kidney disease. Open Cardiovasc Med J. 2011;5:41–48.
- Piecha G, Adamczak M, Ritz E. Dyslipidemia in chronic kidney disease ,Pol Arch Med Wewn. 2009;119:487–492.
- Shah BV, Nair S, Sirsat RA. Outcome of end stage renal disease. J of Nephrol New Series 1992; 2:151-153.
- Koch A, Shan B, Nair S, Sirsat R, Ashavoid T, Nair K. Dyslipidaemia in patients with chronic renal failure and in renal transplant. Journal of Postgraduate Medicine 1994; 40:57-60.
- Mikolasevic et al Dyslipidemia in patients with chronic kidney disease: etiology and management, International Journal of Nephrology and Renovascular Disease 2017:10.
Corresponding Author
Dr Vibha Sushilendu
Senior Resident, Dept of General Medicine, NMCH, Patna
DOI: https://dx.doi.org/10.18535/jmscr/v7i1.66
